BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang H, Zhao L, Li S, Wang J, Feng C, Li T, Du X. N6-Methylandenosine-Related lncRNAs in Tumor Microenvironment Are Potential Prognostic Biomarkers in Colon Cancer. Front Oncol 2021;11:697949. [PMID: 34178697 DOI: 10.3389/fonc.2021.697949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou SZ, Pan YL, Deng QC, Yin CJ, Zhou DJ, Liu ML, Zhou J, Wu XJ. A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs. J Oncol 2023;2023:7797710. [PMID: 36814559 DOI: 10.1155/2023/7797710] [Reference Citation Analysis]
2 Zhang L, Xia J. N6-Methyladenosine Methylation of mRNA in Cell Senescence. Cell Mol Neurobiol 2023;43:27-36. [PMID: 34767142 DOI: 10.1007/s10571-021-01168-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Xiong S, Jin L, Zeng C, Ma H, Xie L, Liu S. An innovative pyroptosis-related long-noncoding-RNA signature predicts the prognosis of gastric cancer via affecting immune cell infiltration landscape. Pathol Oncol Res 2022;28:1610712. [PMID: 36567977 DOI: 10.3389/pore.2022.1610712] [Reference Citation Analysis]
4 Yang HS, Cai HY, Shan SC, Chen TF, Zou JY, Abudurufu M, Luo HH, Lei YY, Ke ZF, Zhu Y. Methylation of N6 adenosine-related long noncoding RNA: effects on prognosis and treatment in 'driver-gene-negative' lung adenocarcinoma. Mol Oncol 2023;17:365-77. [PMID: 36221911 DOI: 10.1002/1878-0261.13323] [Reference Citation Analysis]
5 Zhang L, Chen F, Liang X, Ponnusamy M, Qin H, Lin Z. Crosstalk among long non-coding RNA, tumor-associated macrophages and small extracellular vesicles in tumorigenesis and dissemination. Front Oncol 2022;12:1008856. [DOI: 10.3389/fonc.2022.1008856] [Reference Citation Analysis]
6 Li Z, Liu Y, Yi H, Cai T, Wei Y. Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients. Front Genet 2022;13:947747. [DOI: 10.3389/fgene.2022.947747] [Reference Citation Analysis]
7 Qiao H, Liu L, Chen J, Shang B, Wang L. The functions of N6-methyladenosine (m6A) RNA modifications in colorectal cancer. Med Oncol 2022;39:235. [PMID: 36175777 DOI: 10.1007/s12032-022-01827-4] [Reference Citation Analysis]
8 Maimaiti A, Turhon M, Cheng X, Su R, Kadeer K, Axier A, Ailaiti D, Aili Y, Abudusalamu R, Kuerban A, Wang Z, Aisha M. m6A regulator–mediated RNA methylation modification patterns and immune microenvironment infiltration characterization in patients with intracranial aneurysms. Front Neurol 2022;13:889141. [DOI: 10.3389/fneur.2022.889141] [Reference Citation Analysis]
9 Yang S, Zhou J, Chen Z, Sun Q, Zhang D, Feng Y, Wang X, Sun Y. A novel m7G-related lncRNA risk model for predicting prognosis and evaluating the tumor immune microenvironment in colon carcinoma. Front Oncol 2022;12:934928. [DOI: 10.3389/fonc.2022.934928] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Zheng P, Zhang X, Ren D, Zhang Y. RP11-552D4.1: a novel m6a-related LncRNA associated with immune status in glioblastoma. Aging. [DOI: 10.18632/aging.204177] [Reference Citation Analysis]
11 Song N, Cui K, Zhang K, Yang J, Liu J, Miao Z, Zhao F, Meng H, Chen L, Chen C, Li Y, Shao M, Zhang J, Wang H. The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research. Front Pharmacol 2022;13:933332. [DOI: 10.3389/fphar.2022.933332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Wu Y, Yu B, Li Y, Yu F, Li Z, Chen D, Jiang F, Bo J, Xue H, Lv H, Li H. LINC01006 and miR-3199 Serve as Novel Markers of Poor Prognosis in Colon Cancer and Regulate Cell Proliferation, Migration and Invasion. IJGM 2022;Volume 15:1677-87. [DOI: 10.2147/ijgm.s334701] [Reference Citation Analysis]